Back to Search
Start Over
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
- Source :
-
European journal of haematology [Eur J Haematol] 2018 Oct; Vol. 101 (4), pp. 556-565. Date of Electronic Publication: 2018 Sep 05. - Publication Year :
- 2018
-
Abstract
- Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE <superscript>®</superscript> OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice.<br />Method: Patients scheduled to receive intravenous bortezomib for MM were eligible. The primary objective was to evaluate clinical outcomes, including response, time to response, time to next therapy, treatment-free interval, progression-free survival (PFS), and overall survival (OS). Secondary objectives included safety and healthcare resource utilization.<br />Results: In total, 873 patients with a median of two therapy lines prior to initiating bortezomib were included. The overall response rate (≥partial response) was 69%, including 37% complete response/near-complete response. Median time to response was 1.8 months, median time to next therapy was 9.7 months, and median treatment-free interval was 7.9 months. After 22.6 months' median follow-up, median PFS was 12.0 months and median OS was 36.1 months. The most common adverse events (AEs) were neuropathy not otherwise specified (19%), diarrhea NOS, and thrombocytopenia (each 17%); 230 (26%) patients discontinued bortezomib due to AEs. Of 689 (79%) patients without baseline peripheral neuropathy (PN), the rate of new-onset any-grade PN increased to 51% (12% grade 3/4) by cycle 8. Overall, 244 (28%) patients were hospitalized, 372 (43%) attended an outpatient visit, and 341 (39%) underwent a diagnostic/therapeutic procedure during bortezomib treatment.<br />Conclusion: These prospective real-world data demonstrate the effectiveness and safety of bortezomib-based therapy for RRMM and confirm high response rates and long OS for this population.<br /> (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Bortezomib administration & dosage
Combined Modality Therapy
Comorbidity
Drug Resistance, Neoplasm
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma mortality
Recurrence
Retreatment
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy
Multiple Myeloma pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1600-0609
- Volume :
- 101
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- European journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 30027641
- Full Text :
- https://doi.org/10.1111/ejh.13147